Evidence for angiogenesis in Parkinson's disease, incidental Lewy body disease, and progressive supranuclear palsy

Journal of Neural Transmission

Volumn 119, Issue 1, 2012, Pages 59-71

  Bradaric, Brinda Desai ^a   Patel, Aditiben ^a   Schneider, Julie A ^b,c   Carvey, Paul M ^a,c   Hendey, Bill ^a  

^a RUSH UNIVERSITY   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c RUSH MEDICAL COLLEGE   (United States)

Author keywords

Angiogenesis; Incidental Lewy body disease; Integrin v 3; Microglia; Parkinson's disease; Progressive supranuclear palsy

Indexed keywords

VERY LATE ACTIVATION ANTIGEN 3;

ANGIOGENESIS; ARTICLE; BLOOD BRAIN BARRIER; CELL ACTIVATION; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; FRONTAL CORTEX; HUMAN; IMMUNOCOMPETENT CELL; LOCUS CERULEUS; MICROGLIA; PARKINSON DISEASE; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PUTAMEN; SUBSTANTIA NIGRA PARS COMPACTA;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BRAIN; FEMALE; HUMANS; INTEGRIN ALPHAVBETA3; LEWY BODY DISEASE; MALE; MICROGLIA; NEOVASCULARIZATION, PATHOLOGIC; NEURONS; PARKINSON DISEASE; POSTMORTEM CHANGES; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 84857624257     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-011-0684-8     Document Type: Article

References (82)

1. Akiyama H, Kawamata T, Dedhar S, McGeer PL (1991) Immunohistochemical localization of vitronectin, its receptor and beta-3 integrin in Alzheimer brain tissue. J Neuroimmunol 32:19-28
2. Armstrong RA, Lantos PL, Cairns NJ (2007) Progressive supranuclear palsy (PSP): a quantitative study of the pathological changes in cortical and subcortical regions of eight cases. J Neural Transm 114:1569-1577 (Pubitemid 350212018)
3. Astradsson A, Jenkins BG, Choi JK, Hallett PJ, Levesque MA, McDowell JS, Brownell AL, Spealman RD, Isacson O (2009) The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates - evidence from in vivo neuroimaging studies. Neurobiol Dis 35:348-351
4. Baluk P, McDonald DM (2008) Markers for microscopic imaging of lymphangiogenesis and angiogenesis. Ann NY Acad Sci 1131: 1-12 (Pubitemid 351758499)
5. Baluk P, Lee CG, Link H, Ator E, Haskell A, Elias JA, McDonald DM (2004) Regulated angiogenesis and vascular regression in mice overexpressing vascular endothelial growth factor in airways. Am J Pathol 165:1071-1085 (Pubitemid 39297715)
6. Barcia C, Emborg ME, Hirsch EC, Herrero MT (2004) Blood vessels and parkinsonism. Front Biosci. 9:277-282 (Pubitemid 38925459)
7. Barcia C, Bautista V, Sanchez-Bahillo A, Fernandez-Villalba E, Faucheux B, Poza y Poza M, Fernandez Barreiro A, Hirsch EC, Herrero MT (2005) Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian. J Neural Transm 112:1237-1248 (Pubitemid 41215926)
8. Benner EJ, Banerjee R, Reynolds AD, Sherman S, Pisarev VM, Tsiperson V, Nemachek C, Ciborowski P, Przedborski S, Mosley RL, Gendelman HE (2008) Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS ONE 3:e1376
9. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, Wilson RS (2006a) Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 66:1837-1844 (Pubitemid 44049813)
10. Bennett DA, Schneider JA, Aggarwal NT, Arvanitakis Z, Shah RC, Kelly JF, Fox JH, Cochran EJ, Arends D, Treinkman AD, Wilson RS (2006b) Decision rules guiding the clinical diagnosis of Alzheimer's disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study. Neuroepidemiology. 27:169-176 (Pubitemid 44651437)
11. Bertrand E, Lechowicz W, Szpak GM, Dymecki J (1997) Qualitative and quantitative analysis of locus coeruleus neurons in Parkinson's disease. Folia Neuropathol 35:80-86 (Pubitemid 127535387)
12. Braak H, Del Tredici K (2008) Reply to ''Controversies over the staging of a-synuclein pathology in Parkinson's disease''. Acta Neuropathol 116(1):129-131
13. Braak H, Del Tredici K (2009) Neuroanatomy and pathology of sporadic Parkinson's disease. Adv Anat Embryol Cell Biol 201:1-119
14. Braak H, Del Tredici K (2010) Pathophysiology of sporadic Parkinson's disease. Fortschr Neurol Psychiatr 78 Suppl 1:S2-S4
15. Braak H, Rub U, Gai WP, Del Tredici K (2003) Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm. 110:517-536 (Pubitemid 36543283)
16. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318:121-134 (Pubitemid 39362633)
17. Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray- Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C, Flavell RA, Hirsch EC, Hunot S (2009) Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119:182-192
18. Brooks PC (1996) Role of integrins in angiogenesis. Eur J Cancer 32A:2423-2429
19. Brooks PC, Clark RA, Cheresh DA (1994a) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 264:569-571
20. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA (1994b) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157-1164
21. Carta M, Lindgren HS, Lundblad M, Stancampiano R, Fadda F, Cenci MA (2006) Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J Neurochem 96:1718-1727 (Pubitemid 43351629)
22. Carvey PM, Zhao CH, Hendey B, Lum H, Trachtenberg J, Desai BS, Snyder J, Zhu YG, Ling ZD (2005) 6-Hydroxydopamineinduced alterations in blood-brain barrier permeability. Eur J Neurosci 22:1158-1168 (Pubitemid 41395380)
23. Carvey PM, Hendey B, Monahan AJ (2009) The blood-brain barrier in neurodegenerative disease: a rhetorical perspective. J Neurochem 111:291-314
24. Celesia GG, Wanamaker WM (1976) L-dopa-carbidopa: combined therapy for the treatment of Parkinson's disease. Dis Nerv Syst. 37:123-125
25. Chen X, Lan X, Roche I, Liu R, Geiger JD (2008) Caffeine protects against MPTP-induced blood-brain barrier dysfunction in mouse striatum. J Neurochem 107:1147-1157
26. Chung YC, Ko HW, Bok E, Park ES, Huh SH, Nam JH, Jin BK (2010) The role of neuroinflammation on the pathogenesis of Parkinson's disease. BMB Rep. 43:225-232
27. Croisier E, Moran LB, Dexter DT, Pearce RK, Graeber MB (2005) Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J Neuroinflamm 2:14
28. DelleDonne A, Klos KJ, Fujishiro H, Ahmed Z, Parisi JE, Josephs KA, Frigerio R, Burnett M, Wszolek ZK, Uitti RJ, Ahlskog JE, Dickson DW (2008) Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol 65:1074-1080
29. Desai BS, Schneider JA, Li JL, Carvey PM, Hendey B (2009) Evidence of angiogenic vessels in Alzheimer's disease. J Neural Transm. 116:587-597
30. Dickson DW, Fujishiro H, DelleDonne A, Menke J, Ahmed Z, Klos KJ, Josephs KA, Frigerio R, Burnett M, Parisi JE, Ahlskog JE (2008) Evidence that incidental Lewy body disease is presymptomatic Parkinson's disease. Acta Neuropathol 115: 437-444
31. Fahn S, Przedborski S (2000) Parkinsonism 679-693
32. Faucheux BA, Bonnet AM, Agid Y, Hirsch EC (1999) Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet 353:981-982 (Pubitemid 29132612)
33. Folkman J (2004) Endogenous angiogenesis inhibitors. Apmis. 112: 496-507 (Pubitemid 39626056)
34. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA (1995) Definition of two angiogenic pathways by distinct alpha v integrins. Science. 270:1500-1502 (Pubitemid 3005294)
35. Gerhard A, Trender-Gerhard I, Turkheimer F, Quinn NP, Bhatia KP, Brooks DJ (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. Mov Disord 21:89-93 (Pubitemid 43273758)
36. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364 (Pubitemid 26272076)
37. Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, Lantos PL, McKee A, Tabaton M, Litvan I (1994) Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology. 44:2015-2019 (Pubitemid 24349498)
38. Holley JE, Newcombe J, Whatmore JL, Gutowski NJ (2010) Increased blood vessel density and endothelial cell proliferation in multiple sclerosis cerebral white matter. Neurosci Lett 470:65-70
39. Horton M (1990) Vitronectin receptor: tissue specific expression or adaptation to culture? Int J Exp Pathol 71:741-759 (Pubitemid 20302441)
40. Ishizawa K, Dickson DW (2001) Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration. J Neuropathol Exp Neurol 60: 647-657 (Pubitemid 32523629)
41. Jain RK (2003) Molecular regulation of vessel maturation. Nat Med 9:685-693 (Pubitemid 36749217)
42. Jain RK (2005) Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park). 19:7-16
43. Jonkers N, Sarre S, Ebinger G, Michotte Y (2001) Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat. J Neural Transm. 108:559-570 (Pubitemid 32441871)
44. Josephs KA, Dickson DW (2003) Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. Mov Disord 18:1018-1026 (Pubitemid 37185209)
45. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK (2008) Controversies over the staging of alpha-synuclein pathology in Parkinson's disease. Acta Neuropathol 116:125-128
46. Kalinowski L, Dobrucki LW, Meoli DF, Dione DP, Sadeghi MM, Madri JA, Sinusas AJ (2008) Targeted imaging of hypoxiainduced integrin activation in myocardium early after infarction. J Appl Physiol 104:1504-1512
47. Kanaan NM, Kordower JH, Collier TJ (2008) Age and region-specific responses of microglia, but not astrocytes, suggest a role in selective vulnerability of dopamine neurons after 1-methyl-4- phenyl-1, 2, 3, 6-tetrahydropyridine exposure in monkeys. Glia. 56:1199-1214
48. Kenneth NS, Rocha S (2008) Regulation of gene expression by hypoxia. Biochem J 414:19-29
49. Kirk S, Frank JA, Karlik S (2004) Angiogenesis in multiple sclerosis: is it good, bad or an epiphenomenon? J Neurol Sci 217:125-130 (Pubitemid 38056544)
50. Lahdenranta J, Sidman RL, Pasqualini R, Arap W (2007) Treatment of hypoxia-induced retinopathy with targeted proapoptotic peptidomimetic in a mouse model of disease. Faseb J. 21: 3272-3278 (Pubitemid 47565545)
51. Lindgren HS, Ohlin KE, Cenci MA (2009) Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease. Neuropsychopharmacology. 34:2477-2488
52. McGeer PL, McGeer EG (2008) Glial reactions in Parkinson's disease. Mov Disord 23:474-483
53. McGeer PL, Itagaki S, BoyesBE,McGeerEG(1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 38:1285-1291
54. Milner R, Campbell IL (2003) The extracellular matrix and cytokines regulate microglial integrin expression and activation. J Immunol 170:3850-3858 (Pubitemid 36359256)
55. Milner R, Frost E, Nishimura S, Delcommenne M, Streuli C, Pytela R, Ffrench-Constant C (1997) Expression of alpha vbeta3 and alpha vbeta8 integrins during oligodendrocyte precursor differentiation in the presence and absence of axons. Glia. 21:350-360 (Pubitemid 27526672)
56. Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF (2008) Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 11:109-119
57. Naldini A, Carraro F (2005) Role of inflammatory mediators in angiogenesis. Curr Drug Targets Inflamm Allergy. 4:3-8 (Pubitemid 40584847)
58. Paik DC, Fu C, Bhattacharya J, Tilson MD (2004) Ongoing angiogenesis in blood vessels of the abdominal aortic aneurysm. Exp Mol Med. 36:524-533 (Pubitemid 40129174)
59. Pinkstaff JK, Detterich J, Lynch G, Gall C (1999) Integrin subunit gene expression is regionally differentiated in adult brain. J Neurosci 19:1541-1556 (Pubitemid 29094174)
60. Pogue AI, Lukiw WJ (2004) Angiogenic signaling in Alzheimer's disease. Neuroreport. 15:1507-1510 (Pubitemid 38925253)
61. Rajput AH, Rozdilsky B, Rajput A (1991) Accuracy of clinical diagnosis in parkinsonism - a prospective study. Can J Neurol Sci 18:275-278
62. Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley RL, Gendelman HE (2010) Regulatory T cells attenuate Th17 cellmediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol
63. Roscoe WA, Welsh ME, Carter DE, Karlik SJ (2009) VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE. J Neuroimmunol 209:6-15
64. Schmid-Brunclik N, Burgi-Taboada C, Antoniou X, Gassmann M, Ogunshola OO (2008) Astrocyte responses to injury: VEGF simultaneously modulates cell death and proliferation. Am J Physiol Regul Integr Comp Physiol 295:R864-R873
65. Schneider JA, Arvanitakis Z, Bang W, Bennett DA (2007) Mixed brain pathologies account for most dementia cases in community- dwelling older persons. Neurology. 69:2197-2204 (Pubitemid 350294674)
66. Schneider JA, Aggarwal NT, Barnes L, Boyle P, Bennett DA (2009a) The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis 18:691-701
67. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA (2009b) The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 66:200-208
68. Schultheiss C, Blechert B, Gaertner FC, Drecoll E, Mueller J, Weber GF, Drzezga A, Essler M (2006) In vivo characterization of endothelial cell activation in a transgenic mouse model of Alzheimer's disease. Angiogenesis
69. Shen H, Kannari K, Yamato H, Arai A, Matsunaga M (2003) Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats. Tohoku J Exp Med 199:149-159 (Pubitemid 36519467)
70. Steele JC, Richardson JC, Olszewski J (1964) Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 10:333-359
71. Streit WJ (2006) Microglial senescence: does the brain's immune system have an expiration date? Trends Neurosci 29:506-510 (Pubitemid 44291814)
72. Thirumangalakudi L, Samany PG, Owoso A, Wiskar B, Grammas P (2006) Angiogenic proteins are expressed by brain blood vessels in Alzheimer's disease. J Alzheimers Dis. 10:111-118 (Pubitemid 44401371)
73. Vagnucci AHJ, Li WW (2003) Alzheimer's disease and angiogenesis. Lancet 361:605-608 (Pubitemid 36207483)
74. Wada K, Arai H, Takanashi M, Fukae J, Oizumi H, Yasuda T, Mizuno Y, Mochizuki H (2006) Expression levels of vascular endothelial growth factor and its receptors in Parkinson's disease. Neuroreport. 17:705-709 (Pubitemid 43947927)
75. Wei L, Erinjeri JP, Rovainen CM, Woolsey TA (2001) Collateral growth and angiogenesis around cortical stroke. Stroke. 32: 2179-2184 (Pubitemid 32868119)
76. Westin JE, Lindgren HS, Gardi J, Nyengaard JR, Brundin P, Mohapel P, Cenci MA (2006) Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3, 4-dihydroxyphenyl-L- alanine-induced dyskinesia. J Neurosci 26:9448-9461 (Pubitemid 44396858)
77. Whitton PS (2007) Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 150:963-976 (Pubitemid 46628616)
78. Williams RW, Rakic P (1988) Three-dimensional counting: an accurate and direct method to estimate numbers of cells in sectioned material. J Comp Neurol 278:344-352 (Pubitemid 19004342)
79. Willmann JK, Lutz AM, Paulmurugan R, Patel MR, Chu P, Rosenberg J, Gambhir SS (2008) Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Radiology 248:936-944
80. Wilson RS, Leurgans SE, Boyle PA, Schneider JA, Bennett DA (2010) Neurodegenerative basis of age-related cognitive decline. Neurology 75:1070-1078
81. Yasuda T, Fukuda-Tani M, Nihira T, Wada K, Hattori N, Mizuno Y, Mochizuki H (2007) Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson's disease. Exp Neurol 206:308-317 (Pubitemid 47094775)
82. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong JS, Zhang J (2005) Aggregated alphasynuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 19:533-542 (Pubitemid 40471244)